Serena Williams' revelation on Thursday that she'd lost 31 pounds came with another confession. Fans were angered with Williams' appearance discussing the drug on the 'TODAY' show .

Caleb Luna, assistant professor of feminist studies at the University of California, says having someone like Serena Williams ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication ...

Tennis legend Serena Williams is sharing her journey with weight loss drugs, saying she's lost 31 pounds in 8 months using GLP-1s.

Telehealth company Ro has tapped tennis star Serena Williams as a celebrity patient ambassador for its weight-loss treatments ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...